The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.
ASCO 2024 Oral and Poster Presentations: 2024
ASCO 2024
Collaborative Oral Presentations:
7013: Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study- Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glaß, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor Chow, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Jeremy Abramson
7016: Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)- Maria Lia Palomba, Tanya Siddiqi, Leo Gordon, Manali Kamdar, Matthew Lunning, Alexandre Hirayama, Jeremy Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Rashmi Bhatnagar, Anthony Raviele, Michael Wang
Program Poster Presentation:
6560: Effect of pre-transplant functional status on length of hospital stay in patients undergoing allogeneic hematopoietic stem cell transplant in an outpatient transplant program-Lizamarie Bachier-Rodriguez, Scott Solomon, Asad Bashey, Lawrence Morris, Henry Holland, Melhem Solh, Xu Zhang, Joanna Collins, Adam Drumm, Lan Lei, Catrina Kure, Briana Ford
Collaboratorive Program Poster Presentations:
TPS2678: A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation-Monzr Al Malki, Alla Keyzner, Hyung Suh, Uday Popat, Saar Gill, Yi-Bin Chen, Melhem Solh, Lohith Gowda, Erica Buonomo, Yun Wang, Jim Murray, Gavin MacBeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef
TPS7085: Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy-Armin Ghobadi, Caron Jacobson, Joseph McGuirk, Nirali Shah, John Rossi, Tonia Buchholz, Lizamarie Bachier-Rodriguez, John Baird, Catherine Diefenbach, Umar Farooq, Francisco Hernandez-Ilizaliturri, Iris Isufi, Krish Patel, Sattva Neelapu, Craig Sauter, Jay Spiegel, Michael Tees, John Timmerman, Ginna Laport, Matthew Frank
TPS6586:A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify)-
Naval Daver, Abhishek Maiti, David Sallman, Gail Roboz, Melhem Solh, Filippo Milano, Stephen Strickland, Alireza Eghtedar, Steven Kanner, Guy Ledergor, Donna Marcy, Elizabeth Garner, Brian Francica, McKay Shaw, Kalin Bird, Jennifer Rattan, Enrique Zudaire, Socorro Portella, Pankit Vachhani, Jae Park
ASH Oral and Poster Presentations: 2023
ASH 2023
Collaborative Oral Presentations:
109 The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704- Andrew Artz, MD, MS, Brent R. Logan, PhD, Wael Saber, MD, MS3, Nancy Geller, PhD4*, Anna Bellach, Ph.D., Jianqun Kou, MS, William Wood, MD, MPH, John M. McCarty, MD, Thomas G. Knight, MD, Lyndsey Runaas, Laura Johnston, Jeremy Walston, Ryotaro Nakamura, MD, Tammy Schuler, Asmita Mishra, MD, MBA, Joseph Uberti, MD, PhD, Parastoo B. Dahi, MD, Jennifer N. Saultz, DO, Shannon R McCurdy, MD, Lawrence Morris, MD9, Philip Imus, MD, William J. Hogan, MD, Kalyan Nadiminti, MBBS, Vijaya Raj Bhatt, MD, Deborah Mattila, BA, Bailey Protz, Steven M. Devine, MD, Mary M. Horowitz, MD27 and Mohamed Sorror, MD MSc
330 Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004-
Tanya Siddiqi, MD, David G Maloney, MD, PhD, Saad S. Kenderian, MD, Danielle M Brander, MD, Kathleen Dorritie, MD, Jacob Soumerai, MD, Peter A Riedell, MD, Nirav N. Shah, MD, Rajneesh Nath*, Bita Fakhri, MD, MPH, Deborah M. Stephens, DO, Shuo Ma, MD, PhD, Tatyana Feldman, MD, Scott R. Solomon, MD, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda, MD, PhD
522 Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study- Noam E. Kopmar, MD, Ted Gooley, PhD, Gregory W Roloff, MD, Ibrahim Aldoss, Chenyu Lin, MD, Simone E. Dekker, MD, PhD, Vishal K Gupta, MD, Nikeshan Jeyakumar, MD, Timothy O'connor, MD, Kaitlyn C Dykes, MD, Mohamed Ahmed, Hector Zambrano13*, Danielle Bradshaw, MD14*, Santiago Mercadal, MD15*, Marc Schwartz, MD16*, Sean Tracy, MD, PhD17, Bhagirathbhai Dholaria, MBBS, Michal Kubiak, MD, Akash Mukherjee, MD, Navneet Majhail, MD, Minoo Battiwalla, MD, Luke Mountjoy, DO, Shabaz Malik, MD, Paul Shaughnessy, MD, John Mathews, MD, Aaron C. Logan, MD, PhD, Abdullah Ladha, MD, George Yaghmour, MD, Anjali S. Advani, MD, Maryann Stefan, Caitlin Guzowski, MBA, Rasmus T. Hoeg, MD, Talal Hilal, MD, Jozal Moore, MD, Kristen M. O'Dwyer, MD, Stephanie B. Tsai, MD, MS, Joshua Sasine, MD, Melhem M. Solh, MD, Catherine J. Lee, MD, Vamsi K. Kota, MD, Divya Koura, MD, Muthu Veeraputhiran, MD, Betsy Blunk, Jessica T. Leonard, MD, Caspian H. Oliai, MD, Veronika Bachanova, MD, PhD, Wendy Stock, MD, Ahmed Galal, MD, Vinod Pullarkat, MD, Bijal D. Shah, MD, Rawan Faramand, MD, Lori S. Muffly, MD, Ryan D Cassaday, MD
671 The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia- Timothy E O'Connor, MD, Chenyu Lin, MD, Gregory W Roloff, MD, Amy Zhang, PhD, Ibrahim Aldoss, Rawan Faramand, MD, Noam E. Kopmar, MD, Kaitlyn C Dykes, MD, Nikeshan Jeyakumar, MD, Simone E. Dekker, MD, PhD, Vishal K Gupta, MD, Mohamed Ahmed, Aaron C. Logan, MD, PhD, Hector Zambrano, Danielle Bradshaw, MD, Santiago Mercadal, MD, Marc Schwartz, MD, Sean Tracy, MD, PhD, Michal Kubiak, MD, Akash Mukherjee, MD, Navneet Majhail, MD, Minoo Battiwalla, MD, Luke Mountjoy, DO, Shabaz Malik, MD, John Mathews, MD, Paul Shaughnessy, MD, Abdullah Ladha, MD, George Yaghmour, MD, Anjali S. Advani, MD, Maryann Stefan, Caitlin Guzowski, MBA, Rasmus T. Hoeg, MD, Talal Hilal, MD, Jozal Moore, MD, Joshua Sasine, MD, Melhem M. Solh, MD, Catherine J. Lee, MD, Vamsi K. Kota, MD, Divya Koura, MD, Muthu Veeraputhiran, MD, Betsy Blunk, Jessica T. Leonard, MD, Caspian H. Oliai, MD, Veronika Bachanova, MD, PhD, Wendy Stock, MD, Ryan D Cassaday, MD, Bijal D. Shah, MD, Katharine Miller, PhD, MPH, Lori S. Muffly, MD, Ahmed Galal, MD, Stephanie B. Tsai, MD, MS, Bhagirathbhai Dholaria, MBBS
897 Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation- Shernan G. Holtan, MD, Michael J Martens, Ph, Monzr M. Al Malki, MD, Yvonne Adeduni Efebera, MD, MPH, Carrie L. Kitko, MD, Ran Reshef, MD, MSc, Andrew R. Rezvani, MD, BA, Brian C. Shaffer, MD, Melhem M. Solh, MD, Janny M. Yao, PharmD, Lyndsey Runaas, MD, Hany Elmariah, MD, MS, Karilyn T. Larkin, MD, Najla El Jurdi, MD, Mahasweta Gooptu, MD, Alison W Loren, MD, Aric C. Hall, MD, Amin Alousi, Omer Jamy, MD, William Clark, MD, MS, Leslie Kean, Ami S. Bhatt, Miguel-Angel Perales, MD, Kristy Applegate, Juan WU, Eric Liefer, Nancy DiFronzo, PhD, Richard J. Jones, MD, Mary M. Horowitz, MD, Deborah Mattila, BA, Mehdi Hamadani, MD and Javier Bolanos-Meade, MD, KHS
973 Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated- Mark J. Levis, MD, PhD, Mehdi Hamadani, MD, Brent R. Logan, PhD, Richard J. Jones, MD, Anurag K. Singh, MD, Mark R. Litzow, MD, John R. Wingard, MD, Esperanza B. Papadopoulos, MD, Alexander Perl, Robert J. Soiffer, MD, Celalettin Ustun, MD, Masumi Ueda Oshima, MD, Geoffrey L Uy, MD, Edmund K. Waller, MD, Sumithira Vasu, MD, MBBS, Melhem M. Solh, MD, Asmita Mishra, MD, MBA, Lori S. Muffly, MD, Hee-Je Kim, Matthias Stelljes, MD, Yuho Najima, MD, PhD, Masahiro Onozawa, M.D., Ph.D., Kirsty Thomson, MB ChB, Arnon Nagler, MD, M.Sc, Andrew H. Wei, MBBS, PhD, Guido Marcucci, MD, Nahla Hasabou, MD, Mathew Rosales, PhD, Jason Hill, PhD, Stanley C. Gill, PhD, Rishita Nuthethi, PhD, Denise King, MS, CCRA, Heather Wittsack, MPH, Adam Mendizabel, PhD, Steven M. Devine, MD, Mary M. Horowitz, MD, Yi-Bin Chen, MD, MS
1028 Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3-Paula RodrÃguez Otero, Sikander Ailawadhi, MD, Bertrand Arnulf, MD, PhD, Krina K. Patel, MD, MSc, Michele Cavo, MD*, Ajay K. Nooka, MD, MPH, Salomon Manier, MD, PhD, Natalie S. Callander, MD, Luciano Costa, MD, PhD, Ravi Vij, MD, MBA, Nizar J Bahlis, MD, Philippe Moreau, MD, PhD, Scott R. Solomon, MD, Ingerid Weum Abrahamsen, Rachid Baz, MD, Annemiek Broijl, MD, PhD, Christine Chen, MHPE, MD, FRCPC, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, MD, Anna Truppel-Hartmann, MD, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, MPH, Devender Dhanda, PhD, Jasper Felten, Andrea Caia, Mark Cook, MBChB, PhD, Mihaela Popa-McKiver, MD, PhD, Sergio A. Giralt, MD, FACP
1030 Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) Gregory W Roloff, MD, Ibrahim Aldoss, Noam E. Kopmar, MD, Chenyu Lin, MD, Simone E. Dekker, MD, PhD, Vishal K Gupta, MD, Nikeshan Jeyakumar, MD, Timothy E O'Connor, MD, Amy Zhang, PhD, Katharine Miller, PhD, MPH, Kaitlyn C Dykes, MD, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, MD, Santiago Mercadal, MD, Marc Schwartz, MD, Sean Tracy, MD, PhD, Bhagirathbhai Dholaria, MBBS, Michal Kubiak, MD, Akash Mukherjee, MD*, Navneet Majhail, MD, Minoo Battiwalla, MD, Luke Mountjoy, DO, Shahbaz A. Malik, MD, John Mathews, MD, Paul Shaughnessy, MD, Aaron C. Logan, MD, PhD, Abdullah Ladha, MD, George Yaghmour, MD, Anjali S. Advani, MD, Maryann Stefan, Caitlin Guzowski, MBA, Rasmus T. Hoeg, MD, Talal Hilal, MD, Jozal Moore, MD, Kristen M. O'Dwyer, MD31, Stephanie B. Tsai, MD, MS, Joshua Sasine, MD, Melhem M. Solh, MD, Catherine J. Lee, MD, Vamsi K. Kota, MD, Divya Koura, MD, Muthu Veeraputhiran, MD, Betsy Blunk, Jessica T. Leonard, MD, Veronika Bachanova, MD, PhD, Wendy Stock, MD, Ahmed Galal, MD, Vinod Pullarkat, MD, Ryan D Cassaday, MD, Bijal D. Shah, MD, Rawan Faramand, MD, Lori S. Muffly, MD
Program Posters:
2138 Intrathecal Chemotherapy As Treatment for Chimeric Antigen Receptor T Cell (CAR T) Therapy Associated Neurotoxicity- Melhem M. Solh, MD, Asad Bashey, MD, PhD, Lawrence Morris, MD, Lizamarie Bachier-Rodriguez, MD, H Kent Holland, Xu Zhang, PhD, Katelin C Jackson, Scott R. Solomon, MD
2182 Impact of Allograft T-Cell (CD3) Dose on Outcomes When CD34 Cell Dose Is Capped: Analysis of 811 Consecutive Allogeneic PBSC Transplants from a Single Center- Asad Bashey, MD, PhD, Xu Zhang, PhD, Lawrence Morris, MD, Kent Holland, MD, Lizamarie Bachier-Rodriguez, MD, Melhem M. Solh, MD, Scott R. Solomon, MD
2193 Effect of HLA-DPB1 Mismatch on Incidence and Severity of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation- Scott R. Solomon, MD, Melhem M. Solh, MD, Asad Bashey, MD, PhD, Lizamarie Bachier-Rodriguez, MD, Xu Zhang, PhD, Lawrence Morris, MD, H. Kent Holland, MD
2240 Impact of an HLA-DPB1 Non-Permissive Mismatch By the Revised T Cell Epitope (TCE)-Core Algorithm on Survival Following Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCy)- Scott R. Solomon, MD, Michael T Aubrey, Lizamarie Bachier-Rodriguez, MD, Melhem M. Solh, MD, Katelin C Jackson, Xu Zhang, PhD, Christina Roark, H. Kent Holland, MD, Lawrence Morris, MD, Asad Bashey, MD, PhD
2896 Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival- Melhem M. Solh, MD, Scott R. Solomon, MD, Lawrence Morris, MD, H Kent Holland, Lizamarie Bachier-Rodriguez, MD, Xu Zhang, PhD, Katelin C Jackson, Asad Bashey, MD, PhD
4945 Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)- Melhem M. Solh, MD, Scott R. Solomon, MD, Lawrence Morris, MD, Lizamarie Bachier-Rodriguez, MD, H Kent Holland, Xu Zhang, PhD, Katelin C Jackson, Asad Bashey, MD, PhD
4984 Impact of HLA-DQ Heterodimer Group (G1/G2) Mismatch on Relapse and Survival Following Haploidentical Donor Transplantation- Scott R. Solomon, MD, Michael T Aubrey, Xu Zhang, PhD, Lizamarie Bachier-Rodriguez, MD, Lawrence Morris, MD, H. Kent Holland, MD, Christina Roark, Katelin C Jackson, Asad Bashey, MD, PhD, Melhem M. Solh, MD
Collaborative Posters:
105 Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study- Alison R Sehgal, MD, Daanish Hoda, Peter A Riedell, MD, Nilanjan Ghosh, MD, PhD, Mehdi Hamadani, MD, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, MD, Nina Wagner-Johnston, MD, James Essell, Rajneesh Nath, Scott R. Solomon, MD, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A Chow, MD, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon, MD
2913 Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels- Ewa Lech MaraÅ„da, Prof, Elżbieta Patkowska, MD, Natalia Jakacka, MD, Camille N. Abboud, MD, Howard A. Burris, MD, Scott R. Solomon, MD, Noemi Angelosanto, MD, Tomasz Rzymski, PhD, Peter Littlewood, PhD, Kamil KuÅ›, PhD, Agnieszka Sroka-Porada, MSc, Renata Dudziak, MD, Hendrik Nogai, MD, Axel Glasmacher, MD, Terrence Bradley, MD, Gautam Borthakur, MD, Elie Mouhayar, MD, PaweÅ‚ Steckiewicz, MD, Sylwia KoÅ›ciółek- ZgÃdka, MD, Agata SzymaÅ„ska, MD, Jan Maciej Zaucha, Prof
2916 Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study- Jeffrey Lancet, MD, Farhad Ravandi, MD, MBBS, Pau Montesinos, PhD, MD, Jacqueline C. Barrientos, MD, Talha Badar, MD, Adrián Alegre, MD, MPH, Asad Bashey, MD, PhD, Juan Miguel Bergua Burgues, Lorenzo Brunetti, MD, Emily K Curran, MD, David C. Christian de Leeuw, MD, PhD, Enrico Derenzini, MD, Geert A. Huls, Prof., Jeroen J.W.M. Janssen, MD, PhD, Deepa Jeyakumar, MD, Mojca Jongen-Lavrencic, MD, PhD, Ashwin Kishtagari, MBBS, Maria-Victoria Mateos, Daniel Morillo, MD, Alessandro Rambaldi, M.D., Aaron S. Rosenberg, MD, Gary J. Schiller, MD, Uzma Ahmed, MD, MS, Alexandru Cacovean, MD, Stephan W. Morris, MD, Courtney Follit, PhD, Brian Munneke, PhD, Ganesh Waghmare, MD, MPH, Clarissa Mandap, BSN, Mona Vimal, MS, Thomas Butler, MS, MBA, Hetty E. Carraway, MD, MBA
3502 Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)-
Chenyu Lin, MD, Stephanie B. Tsai, MD, MS, Gregory W Roloff, MD, Amy Zhang, PhD, Ibrahim Aldoss, Noam E. Kopmar, MD, Simone E. Dekker, MD, PhD, Nikeshan Jeyakumar, MD*, Vishal K Gupta, MD, Timothy E O'Connor, MD, Kaitlyn C Dykes, MD, Mohamed Ahmed, Bhagirathbhai Dholaria, MBBS, Hector Zambrano, Danielle Bradshaw, MD, Aaron C. Logan, MD, PhD, Sean Tracy, MD, PhD, Michal Kubiak, MD, Melhem M. Solh, MD, Santiago Mercadal, MD, Marc Schwartz, MD, Akash Mukherjee, MD, Minoo Battiwalla, MD, Paul Shaughnessy, MD, Navneet Majhail, MD, Luke Mountjoy, DO, Shahbaz A. Malik, MD, John Mathews, MD, Abdullah Ladha, MD, Anjali S. Advani, MD, Maryann Stefan, Caitlin Guzowski, MBA, Rasmus T. Hoeg, MD, Talal Hilal, MD, Jozal Moore, MD, Kristen M. O'Dwyer, MD, Joshua Sasine, MD, Catherine J. Lee, MD, Vamsi K. Kota, MD, Divya Koura, MD9, Muthu Veeraputhiran, MD, Betsy Blunk, Jessica T. Leonard, MD, Caspian H. Oliai, MD, Veronika Bachanova, MD, PhD, Wendy Stock, MD, Vinod Pullarkat, MD, Ryan D Cassaday, MD, Katharine Miller, PhD, MPH, Lori S. Muffly, MD, Ahmed Galal, MD, Bijal D. Shah, MD, Rawan Faramand, MD
3505 Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study- Maria Lia Palomba, MD, Tanya Siddiqi, MD, Leo I. Gordon, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, Alexandre V Hirayama, MD, Jeremy S. Abramson, MD, Jon E. Arnason, MD, Nilanjan Ghosh, MD, PhD, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, MD, Ana Kostic, MD, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang, MD
4761 Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM)-
Cesar Rodriguez, MD, Scott R. Solomon, MD, Barry Paul, Omar Nadeem, MD, Meenal Patel, Jian Wang, Rongda Xu, Melissa Junttila, PhD, Anneleen Daemen, PhD, Subhash Katewa, PhD, Pratik S Multani, MD, MS, Wilson I. Gonsalves, MD
4877 The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)- Ibrahim Aldoss, Gregory W Roloff, MD, Anjali S. Advani, MD, Noam E. Kopmar, MD, Chenyu Lin, MD, Simone E. Dekker, MD, PhD, Vishal K Gupta, MD, Nikeshan Jeyakumar, MD*, Timothy E O'Connor, MD, Amy Zhang, PhD, Katharine Miller, PhD, MPH, Kaitlyn C Dykes, MD, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, MD, Santiago Mercadal, MD Marc Schwartz, MD, Sean Tracy, MD, PhD, Bhagirathbhai Dholaria, MBBS, Michal Kubiak, MD, Akash Mukherjee, MD, Navneet Majhail, MD, Minoo Battiwalla, MD, Luke Mountjoy, DO, Shahbaz A. Malik, MD, John Mathews, MD, Paul Shaughnessy, MD, Aaron C. Logan, MD, PhD, Abdullah Ladha, MD, George Yaghmour, MD, Maryann Stefan, Caitlin Guzowski, MBA, Rasmus T. Hoeg, MD, Talal Hilal, MD, Jozal Moore, MD, Kristen M. O'Dwyer, MD, Stephanie B. Tsai, MD, MS9, Joshua Sasine, MD, Melhem M. Solh, MD, Catherine J. Lee, MD, Vamsi K. Kota, MD, Divya Koura, MD, Muthu Veeraputhiran, MD, Betsy Blunk, Jessica T. Leonard, MD, Caspian H. Oliai, MD, Veronika Bachanova, MD, PhD, Wendy Stock, MD, Ahmed Galal, MD, Vinod Pullarkat, MD, Ryan D Cassaday, MD, Bijal D. Shah, MD, Rawan Faramand, MD and Lori S. Muffly, MD
4921 A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT- MHD Monzr M. Al Malki, MD, Melhem M. Solh, MD, Anurag K. Singh, MD, Rushang D. Patel, MD, PhD, Denis-Claude Roy, MD, Agata Drewniak, PhD*, Gu Mi, PhD, Lorraine Tracey, PhD, Giovanni Abbadessa, MD, PhD, Richard E. Champlin, MD